Oxaliplatin-related acute myelogenous leukemia
Oxaliplatin-related acute myelogenous leukemia
复制标题
DOI：
10.1634/theoncologist.11-3-261
复制
发表时间：
2006-03-01
期刊：
影响因子：
5.8
通讯作者：
Locker, Gershon Y.
中科院分区：
文献类型：
--
作者：
Carneiro, Benedito A.;Kaminer, Lynne;Locker, Gershon Y.
1例56岁女性，诊断为低分化盲肠腺癌，转移至卵巢、网膜和乙状结肠，接受12个周期的5-氟尿嘧啶、luecovorin和奥沙利铂输注（FOLFOX-4方案）后缓解。13个月后，诊断为盆腔复发，患者接受了9个周期的FOLFOX-6加贝伐单抗治疗，导致临床完全缓解，但出现全血细胞减少症。骨髓活检与治疗相关的急性粒细胞白血病一致。染色体分析显示结构重排，5、7、20和21号染色体长臂部分缺失，以及8号染色体三体和3、11号染色体丢失。诱导化疗导致病情缓解，但患者在两个月后死于结肠癌进展的并发症。白血病很可能与奥沙利铂给药相关。
A 56-year-old woman diagnosed with a poorly differentiated cecal adenocarcinoma with metastases to ovaries, omentum, and sigmoid colon went into remission after 12 cycles of infusional 5-fluorouracil, luecovorin, and oxaliplatin (FOLFOX-4 regimen). Thirteen months later, a pelvic recurrence was diagnosed, and the patient received nine cycles of FOLFOX-6 plus bevacizumab, resulting in a clinical complete response but the development of pancytopenia. Bone marrow biopsy was consistent with therapy-related acute myelogeuous leukemia. Chromosome analysis showed structural rearrangements with partial deletions of the long arms of chromosomes 5,7,20, and 21, as well as trisomy of chromosome 8 and losses of chromosomes 3 and 11. Induction chemotherapy led to remission, but the patient died two months later from complications of colon cancer progression. It is likely that the leukemia was related to the oxaliplatin administration.